Drug Trial Radar · NCT00124475
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,035
Actual
Start
Dec 2004
Primary completion
Oct 2006
Study completion Sep 2007
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.
Conditions
- Hand Dermatoses
Interventions
alitretinoinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Physicians global assessment
- at week 12 or 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Thomas Ruzicka, MD
Düsseldorf, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.